亚太药业(002370.SZ):2020年度业绩扭亏为盈至2727.5万元
格隆汇3月26日丨亚太药业(002370.SZ)披露2020年年度报告,实现营业收入5.15亿元,同比下降27.41%;归属于上市公司股东的净利润2727.5万元,上年同期亏损19.4亿元(调整后);归属于上市公司股东的扣除非经常性损益的净亏损1.43亿元,上年同期亏损19.4亿元(调整后);基本每股收益0.05元。
2020年度,面对新冠肺炎疫情及复杂多变的国内外形势,公司上下共同努力,在做好疫情防控的同时,积极组织复工复产,最大限度减少疫情对公司经营带来的不利影响。公司持续专注医药制造业,坚持研发创新为导向,不断优化产品管线,加大市场开拓力度,合理安排和使用资金,确保公司稳定发展。公司本期业绩实现扭亏为盈,主要系公司柯桥厂区房屋拆迁补偿所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.